Value-based pricing: Who should set drug prices in the UK?
This article was originally published in Scrip
Executive Summary
While the UK's NHS and pharma sector ponder who may end up negotiating drug prices in light of a new white paper, health economists Stuart Carroll, Neil Hawkins and David A Scott contemplate four options which keep NICE very much in the picture
You may also be interested in...
Paradox Of China Biotech And What Lies Ahead In 2023
The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take the pulse of the sector as the Year of the Rabbit starts.
'Pivotal Time For CROs': ICON CEO Cutler On Changing APAC Trial Trends
The CEO of one the global top-five CROs points out a larger opportunity in decentralized trials that might be a “game changer” in the global pharma industry over the next five years. He also refers to the need to accept new technologies by both clinical trial sites and regulators.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Merck & Co. tells Scrip oncology will remain a key priority; J&J is responsibly cautious on growth; Takeda pays big for HutchMed drug; industry looks at likely US IRA impact; and lecanemab misses out on EU fast-track treatment.